These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 23221052)

  • 1. [Clinical characteristics of non-alcoholic steatohepatitis (NASH) patients who progressed from F3 stage fibrosis to cirrhotic NASH].
    Kawanaka M; Oka T; Urata N; Kimura T; Nakamura J; Goto D; Yamato R; Nishino K; Suehiro M; Kawamoto H; Yamada G
    Nihon Shokakibyo Gakkai Zasshi; 2012 Dec; 109(12):2042-8. PubMed ID: 23221052
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management.
    McPherson S; Hardy T; Henderson E; Burt AD; Day CP; Anstee QM
    J Hepatol; 2015 May; 62(5):1148-55. PubMed ID: 25477264
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials.
    Harrison SA; Wong VW; Okanoue T; Bzowej N; Vuppalanchi R; Younes Z; Kohli A; Sarin S; Caldwell SH; Alkhouri N; Shiffman ML; Camargo M; Li G; Kersey K; Jia C; Zhu Y; Djedjos CS; Subramanian GM; Myers RP; Gunn N; Sheikh A; Anstee QM; Romero-Gomez M; Trauner M; Goodman Z; Lawitz EJ; Younossi Z; ;
    J Hepatol; 2020 Jul; 73(1):26-39. PubMed ID: 32147362
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Potential Role of Fatigue in Identifying Patients With NASH and Advanced Fibrosis Who Experience Disease Progression.
    Younossi ZM; Stepanova M; Myers RP; Younossi I; Henry L
    Clin Gastroenterol Hepatol; 2023 Apr; 21(4):970-977.e1. PubMed ID: 35533993
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver.
    Pais R; Charlotte F; Fedchuk L; Bedossa P; Lebray P; Poynard T; Ratziu V;
    J Hepatol; 2013 Sep; 59(3):550-6. PubMed ID: 23665288
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NASH and cryptogenic cirrhosis: a histological analysis.
    Caldwell SH; Lee VD; Kleiner DE; Al-Osaimi AM; Argo CK; Northup PG; Berg CL
    Ann Hepatol; 2009; 8(4):346-52. PubMed ID: 20009134
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Progression from Nonalcoholic Fatty Liver to Nonalcoholic Steatohepatitis Cirrhosis Confirmed by Liver Histology after 14 Years.
    Kawanaka M; Nishino K; Morimoto Y; Ishii K; Tanikawa T; Urata N; Suehiro M; Sasai T; Haruma K; Kawamoto H
    Intern Med; 2021 May; 60(9):1397-1401. PubMed ID: 33281161
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low clinical relevance of the nonalcoholic fatty liver disease activity score (NAS) in predicting fibrosis progression.
    Ekstedt M; Franzén LE; Mathiesen UL; Kechagias S
    Scand J Gastroenterol; 2012 Jan; 47(1):108-15. PubMed ID: 22126450
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The clinical utility of biomarkers and the nonalcoholic steatohepatitis CRN liver biopsy scoring system in patients with nonalcoholic fatty liver disease.
    Malik R; Chang M; Bhaskar K; Nasser I; Curry M; Schuppan D; Byrnes V; Afdhal N
    J Gastroenterol Hepatol; 2009 Apr; 24(4):564-8. PubMed ID: 19378390
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EVALUATION OF PROGRESSION OF HEPATIC FIBROSIS IN A GROUP OF PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE ACCOMPANIED FOR 10 YEARS.
    Castro PCS; Alberton HCP; Pedroso MLA; Morsoletto DBG; Pissaia Junior A; Ivantes CAP
    Arq Gastroenterol; 2019; 56(3):256-260. PubMed ID: 31633721
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical and histological features of non-alcoholic fatty liver disease].
    Shi JP; Xun YH; Hu CB; Zhang L; Liu H; Lou GQ; Fan JG
    Zhonghua Gan Zang Bing Za Zhi; 2009 Nov; 17(11):812-6. PubMed ID: 19958638
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of liver histology between patients with non-alcoholic steatohepatitis and patients with alcoholic steatohepatitis in Japan.
    Morita Y; Ueno T; Sasaki N; Kuhara K; Yoshioka S; Tateishi Y; Nagata E; Kage M; Sata M
    Alcohol Clin Exp Res; 2005 Dec; 29(12 Suppl):277S-81S. PubMed ID: 16385236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD.
    Hagström H; Nasr P; Ekstedt M; Hammar U; Stål P; Hultcrantz R; Kechagias S
    J Hepatol; 2017 Dec; 67(6):1265-1273. PubMed ID: 28803953
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluating the association of serum ferritin and hepatic iron with disease severity in non-alcoholic fatty liver disease.
    Buzzetti E; Petta S; Manuguerra R; Luong TV; Cabibi D; Corradini E; Craxì A; Pinzani M; Tsochatzis E; Pietrangelo A
    Liver Int; 2019 Jul; 39(7):1325-1334. PubMed ID: 30851216
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-alcoholic fatty liver disease - histological scoring systems: a large cohort single-center, evaluation study.
    Rastogi A; Shasthry SM; Agarwal A; Bihari C; Jain P; Jindal A; Sarin S
    APMIS; 2017 Nov; 125(11):962-973. PubMed ID: 29076589
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disease progression of nonalcoholic steatohepatitis in Taiwanese patients: a longitudinal study of paired liver biopsies.
    Lin TY; Yeh ML; Huang CF; Huang CI; Dai CY; Hsieh MH; Chen SC; Huang JF; Yu ML; Chuang WL
    Eur J Gastroenterol Hepatol; 2019 Feb; 31(2):224-229. PubMed ID: 30308578
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive value of ALT levels for non-alcoholic steatohepatitis (NASH) and advanced fibrosis in non-alcoholic fatty liver disease (NAFLD).
    Verma S; Jensen D; Hart J; Mohanty SR
    Liver Int; 2013 Oct; 33(9):1398-405. PubMed ID: 23763360
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years.
    Wong VW; Wong GL; Choi PC; Chan AW; Li MK; Chan HY; Chim AM; Yu J; Sung JJ; Chan HL
    Gut; 2010 Jul; 59(7):969-74. PubMed ID: 20581244
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does hepatocellular carcinoma in non-alcoholic steatohepatitis exist in cirrhotic and non-cirrhotic patients?
    Chagas AL; Kikuchi LO; Oliveira CP; Vezozzo DC; Mello ES; Oliveira AC; Cella LC; Herman P; Bachella T; Caldwell SH; Alves VA; Carrilho FJ
    Braz J Med Biol Res; 2009 Oct; 42(10):958-62. PubMed ID: 19787150
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predicting fibrosis worsening in obese patients with NASH through parenchymal fibronectin, HOMA-IR, and hypertension.
    Sorrentino P; Terracciano L; D'Angelo S; Ferbo U; Bracigliano A; Vecchione R
    Am J Gastroenterol; 2010 Feb; 105(2):336-44. PubMed ID: 19861959
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.